Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "AXA"

48 News Found

U.S FDA authorises EaseVRx, immersive virtual reality for pain relief
Drug Approval | November 17, 2021

U.S FDA authorises EaseVRx, immersive virtual reality for pain relief

EaseVRx employs the principles of cognitive behavioural therapy and other behavioural therapy techniques for the reduction of pain and pain interference


Mandaviya launches the sixth edition of National Formulary of India (NFI)
Public Health | October 29, 2021

Mandaviya launches the sixth edition of National Formulary of India (NFI)

The NFI is published to promote the rational use of medicines in the country.


Indian Pharma Market witnesses rise in volumes and prices in September.
News | October 28, 2021

Indian Pharma Market witnesses rise in volumes and prices in September.

Acute therapies continue to report strong growth compared to chronic ones.


Gland Pharma receives tentative nod for Sugammadex injection
Drug Approval | October 09, 2021

Gland Pharma receives tentative nod for Sugammadex injection

The injection is used to reverse the effects of the muscle relaxants given to patients during surgery


Roche withdraws the US accelerated approval for Tecentriq
Drug Approval | August 28, 2021

Roche withdraws the US accelerated approval for Tecentriq

Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider


Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra
News | August 26, 2021

Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra

Domestic business was up 41.9% YoY and 27.7% QoQ


Sun Pharma acquires rights for Oxra, Oxramet and Oxraduo from AstraZeneca
News | May 28, 2021

Sun Pharma acquires rights for Oxra, Oxramet and Oxraduo from AstraZeneca

Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021


Outlook promising for Cipla: HDFC Securities
News | May 18, 2021

Outlook promising for Cipla: HDFC Securities

The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.